Aquavit Files Investigation of New Drug for New Botulinum Toxin
Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.
Aquavit Pharmaceuticals, Inc. has submitted to the U.S. FDA an Investigation of New Drug package for a new botulinum toxin, DTX-021.
A surgical team at Rutgers and University Hospital is using robotics to improve breast reconstruction outcomes, with potential applications across other reconstructive procedures.